Milne S. Mannino D. Sin D.D.

Asthma-COPD overlap and chronic airflow obstruction: definitions, management, and unanswered questions.

J Allergy Clin Immunol Pract. 2020; 8: 483-495

Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome?.

J Allergy Clin Immunol. 2016; 138: 977-983

What is asthma chronic obstructive pulmonary disease overlap?.

Clin Chest Med. 2020; 41: 395-403Global Initiative for Chronic Obstructive Lung Disease

Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease.

(Available at) (Accessed Dec 4th, 2021)Global Inititative for Asthma

Global strategy for asthma management and prevention.

(Available at) (Accessed Dec 4th, 2021)

The many faces of asthma-chronic obstructive pulmonary disease overlap.

Curr Opin Pulm Med. 2019; 25: 1-10Tu X. Donovan C. Kim R.Y. et al.

Asthma-COPD overlap: current understanding and the utility of experimental models.

Eur Respir Rev. 2021; 30: 190185Mekov E. Nuñez A. Sin D.D. et al.

Update on asthma-COPD overlap (ACO): a narrative review.

Int J Chron Obstruct Pulmon Dis. 2021; 16: 1783-1799

Asthma-COPD overlap.

Curr Pulmonol Rep. 2022; (Epub ahead of print)https://doi.org/10.1007/s13665-021-00284-0Rogliani P. Ora J. Puxeddu E. et al.

Airflow obstruction: is it asthma or is it COPD?.

Int J Chron Obstruct Pulmon Dis. 2016; 11: 3007-3013Yanagisawa S. Ichinose M.

Definition and diagnosis of asthma-COPD overlap (ACO).

Allergol Int. 2018; 67: 172-178

Asthma-COPD overlap: what are the important questions?.

Chest. 2022; 161: 330-344Kobayashi S. Hanagama M. Yamanda S. et al.

Inflammatory biomarkers in asthma-COPD overlap syndrome.

Int J Chron Obstruct Pulmon Dis. 2016; 11: 2117-2123Cazzola M. Puxeddu E. Ora J. et al.

Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers.

Mol Diagn Ther. 2019; 23: 603-614Cazzola M. Ora J. Cavalli F. et al.

Treatable mechanisms in asthma.

Mol Diagn Ther. 2021; 25: 111-121Shi B. Li W. Hao Y. et al.

Characteristics of inflammatory phenotypes among patients with asthma: relationships of blood count parameters with sputum cellular phenotypes.

Allergy Asthma Clin Immunol. 2021; 17: 47de Llano L.P. Cosío B.G. Iglesias A. et al.

Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach.

Int J Chron Obstruct Pulmon Dis. 2018; 13: 591-601Shirai T. Hirai K. Gon Y. et al.

Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap.

J Allergy Clin Immunol Pract. 2019; 7: 134-145

Can we define asthma-COPD overlap (ACO) by biomarkers?.

J Allergy Clin Immunol Pract. 2019; 7: 146-147Pérez de Llano L. Martínez-Moragón E. Plaza Moral V. et al.

Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain.

ENEAS Study Respir Med. 2019; 151: 49-54Ray A. Camiolo M. Fitzpatrick A. et al.

Are we meeting the promise of endotypes and precision medicine in asthma?.

Physiol Rev. 2020; 100: 983-1017Abdel-Aziz M.I. Neerincx A.H. Vijverberg S.J. et al.

Omics for the future in asthma.

Semin Immunopathol. 2020; 42: 111-126Reddel H.K. Vestbo J. Agustí A. et al.

Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.

Eur Respir J. 2021; 58: 2003927Ekerljung L. Mincheva R. Hagstad S. et al.

Prevalence, clinical characteristics and morbidity of the Asthma-COPD overlap in a general population sample.

J Asthma. 2018; 55: 461-469Desai M. Oppenheimer J. Tashkin D.P.

Asthma-chronic obstructive pulmonary disease overlap syndrome: What we know and what we need to find out.

Ann Allergy Asthma Immunol. 2017; 118: 241-245Heaney L.G. McGarvey L.P.

Personalised medicine for asthma and chronic obstructive pulmonary disease.

Respiration. 2017; 93: 153-161Maselli D.J. Hanania N.A.

Management of asthma COPD overlap.

Ann Allergy Asthma Immunol. 2019; 123: 335-344Japanese Respiratory Society

The JRS guidelines for the management of ACO 2018. (In Japanese).

Medical Review, Tokyo2018

[Guidelines for asthma management. (In Spanish)].

Arch Bronconeumol. 2015; 51: 2-54Gaspar Marques J. Lobato M. Leiria Pinto P. et al.

Asthma and COPD "overlap": a treatable trait or common several treatable-traits?.

Eur Ann Allergy Clin Immunol. 2020; 52: 148-159Morissette M. Godbout K. Côté A. et al.

Asthma COPD overlap: Insights into cellular and molecular mechanisms.

Mol Aspects Med. 2022; 85: 101021Brightling C.E. Bleecker E.R. Panettieri Jr., R.A. et al.

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.

Lancet Respir Med. 2014; 2: 891-901Pavord I.D. Chanez P. Criner G.J. et al.

Mepolizumab for eosinophilic chronic obstructive pulmonary disease.

N Engl J Med. 2017; 377: 1613-1629Hanania N.A. Chipps B.E. Griffin N.M. et al.

Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of PROSPERO.

J Allergy Clin Immunol. 2019; 143: 1629-1633Akar-Ghibril N. Casale T. Custovic A. et al.

Allergic endotypes and phenotypes of asthma.

J Allergy Clin Immunol Pract. 2020; 8: 429-440

Eosinophilic vs. neutrophilic asthma.

Curr Pulmonol Rep. 2020; 9: 28-35Cazzola M. Ora J. Cavalli F. et al.

An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease.

Biologics. 2021; 15: 363-374Bateman E.D. Reddel H.K. van Zyl-Smit R.N. et al.

The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases?.

Lancet Respir Med. 2015; 3: 719-728